Increased CSF E-Selectin in Clinical Alzheimer's Disease without Altered CSF Aβ42 and Tau
- PMID: 26401768
- DOI: 10.3233/JAD-150420
Increased CSF E-Selectin in Clinical Alzheimer's Disease without Altered CSF Aβ42 and Tau
Abstract
Clinically diagnosed Alzheimer's disease (AD) is pathologically heterogeneous. In this multicenter cohort of 215 clinically diagnosed AD patients and 249 controls, E-selectin and vascular cell adhesion molecule 1 (VACM-1) were measured along with amyloid-β peptide 1-42 (Aβ42) and tau. We discovered that E-selectin, a biomarker of endothelial function/vascular injury, was inversely correlated with cerebrospinal fluid (CSF) tau/Aβ42 ratio and significantly elevated in clinical AD patients without the typical AD CSF biomarker signature (i.e., low tau/Aβ42 ratio) compared to those with the signature. These findings suggest that E-selectin may be an objective biomarker related to vascular mechanisms contributing to dementia.
Keywords: Alzheimer’s disease; Aβ42; E-selectin; biomarkers; cerebrospinal fluid; cerebrovascular disease; tau; vascular cell adhesion molecule 1.
Similar articles
-
Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.J Alzheimers Dis. 2015;44(2):525-39. doi: 10.3233/JAD-141725. J Alzheimers Dis. 2015. PMID: 25391385
-
High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.Arch Neurol. 1998 Jul;55(7):937-45. doi: 10.1001/archneur.55.7.937. Arch Neurol. 1998. PMID: 9678311 Clinical Trial.
-
Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.J Alzheimers Dis. 2016;51(4):1069-83. doi: 10.3233/JAD-150731. J Alzheimers Dis. 2016. PMID: 26923009
-
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease.Alzheimers Res Ther. 2019 Apr 22;11(1):34. doi: 10.1186/s13195-019-0485-0. Alzheimers Res Ther. 2019. PMID: 31010420 Free PMC article. Review.
-
Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.Neurobiol Aging. 2017 Apr;52:196-213. doi: 10.1016/j.neurobiolaging.2016.02.034. Neurobiol Aging. 2017. PMID: 28317649 Review.
Cited by
-
Peripheral Markers of Vascular Endothelial Dysfunction Show Independent but Additive Relationships with Brain-Based Biomarkers in Association with Functional Impairment in Alzheimer's Disease.J Alzheimers Dis. 2021;80(4):1553-1565. doi: 10.3233/JAD-200759. J Alzheimers Dis. 2021. PMID: 33720880 Free PMC article.
-
Clinical significance of soluble adhesion molecules in anti-NMDAR encephalitis patients.Ann Clin Transl Neurol. 2019 Apr 11;6(5):945-953. doi: 10.1002/acn3.740. eCollection 2019 May. Ann Clin Transl Neurol. 2019. PMID: 31139692 Free PMC article.
-
Immune-related signature of periodontitis and Alzheimer's disease linkage.Front Genet. 2023 Oct 2;14:1230245. doi: 10.3389/fgene.2023.1230245. eCollection 2023. Front Genet. 2023. PMID: 37849501 Free PMC article.
-
Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer's disease.Alzheimers Dement. 2018 Aug;14(8):1052-1062. doi: 10.1016/j.jalz.2018.02.015. Epub 2018 Mar 28. Alzheimers Dement. 2018. PMID: 29604263 Free PMC article.
-
The blood-brain barrier in Alzheimer's disease.Neurobiol Dis. 2017 Nov;107:41-56. doi: 10.1016/j.nbd.2016.07.007. Epub 2016 Jul 15. Neurobiol Dis. 2017. PMID: 27425887 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
